Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jitai is a Traditional Chinese Medicine (TCM) formulation primarily used in China for the treatment of opioid withdrawal symptoms and the prevention of relapse in heroin-dependent individuals. It is composed of approximately 15 herbal ingredients, including *Corydalis yanhusuo*, *Salvia miltiorrhiza*, *Panax ginseng*, and *Angelica sinensis*. The formulation is designed to alleviate physical withdrawal symptoms, reduce psychological cravings, and restore physiological balance post-detoxification. Clinical studies, often led by institutions like the Shanghai Mental Health Center, have evaluated its efficacy both as a monotherapy and in combination with psychosocial interventions. Its mechanism is complex and multi-targeted, involving the modulation of the endogenous opioid system, dopaminergic neurotransmission, and the hypothalamic-pituitary-adrenal (HPA) axis. Jitai is regulated as a pharmaceutical product in China and is typically administered orally in tablet or capsule form.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on jitai.